RaeSedo Inc. awarded $3.4M STTR Grant to Develop New Asthma Therapies
RaeSedo Inc., a spin-out of the University of Arizona developing novel therapies for asthma, is pleased to announce the award of a Phase 2 Small Business Technology Transfer (STTR) grant awarding $3.4 million over two years to continue developing potential therapeutics. Founded and led by researchers from the University of Arizona, RaeSedo Inc. moves into this next …
RaeSedo Inc. awarded $3.4M STTR Grant to Develop New Asthma Therapies Read More »
Small Peptide Derivatives Within the Carbohydrate Recognition Domain of SP-A2 Modulate Asthma Outcomes in Mouse Models and Human Cells
Surfactant Protein-A (SP-A) plays a crucial role in asthma, but genetic variation can lead to dysfunction. Researchers investigated a specific genetic change at position 223 in SP-A2, finding that individuals with the major variant (223Q) had better lung function, reduced inflammation, and improved asthma control. In mouse models and cells from asthmatic participants, they also showed that SP-A 223Q peptides had anti-inflammatory effects, suggesting their potential as therapeutic agents for asthma.
SSTR awarded to RaeSedo, LLC: Development of surfactant protein A-derived peptidomimetics for the treatment of asthma
Drs. Monica Kraft and Julie Ledford received SSTR funding for a Phase I proposal to develop new, short peptide derivatives and mimetics of the active region of surfactant protein-A (SP-A), a protein that regulates key innate immune functions in the lung, and perform a drug screen that identifies those most active and stable with similar …
Drs. Monica Kraft and Julie Ledford Win $10K ‘Shark Tank’ Prize
The “sharks” ultimately invested in Monica Kraft, MD, and Julie Ledford, PhD, for their pitch on a new, inhaled therapeutic for the treatment of asthma and potentially even COPD, cystic fibrosis and pneumonia. The duo was presented with a check for $10,000 at the end of the competition.
Surfactant Protein-A protects against IL-13-induced inflammation in asthma
The lung surfactant proteins are recognized as critical not only for their role in lowering lung surface tension but also in innate host defense. Reports have shown that some asthmatic patients have decreased levels of one member of this protein family in particular, surfactant protein-A (SP-A). Our studies set out to determine the contribution of …
Surfactant Protein-A protects against IL-13-induced inflammation in asthma Read More »